PTC Therapeutics 2023 revenue up 34% to $938M; guides 2024 revenue $600-680M

PTC THERAPEUTICS, INC.

2023-FY EPS reported -$8.37 revenue$937,822,000

Total revenue $937.8M (+34% YoY); net loss $626.6M vs $559.0M in 2022.
DMD franchise: Translarna $356M, Emflaza $255M; Evrysdi royalty + milestone $268.9M.
Cash and securities $876.7M vs $410.7M a year ago; debt extinguishment loss $137.6M.
Pipeline: sepiapterin MAA submission in Mar 2024, NDA by Q3 2024; vatiquinone NDA expected late 2024.
2024 guidance: total revenue $600-680M (down from $938M); GAAP R&D+SG&A $740-835M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

PTC THERAPEUTICS, INC. reported the fourth quarter and full year ended December 31, 2023 results: revenue Total revenue was $307.1 million for the fourth quarter of 2023... Total revenue was $937.8 million for full year 2023.

Period: the fourth quarter and full year ended December 31, 2023
Revenue: Total revenue was $307.1 million for the fourth quarter of 2023... Total revenue was $937.8 million for full year 2023
Result: reported results

Exact text from the filing

PTC Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and fiscal year ended December 31, 2023.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

PTC THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-24-002189

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.